Search

Your search keyword '"Punt, C. J. A."' showing total 494 results
Start Over Author "Punt, C. J. A."
494 results on '"Punt, C. J. A."'

1. Perioperative Systemic Therapy Versus Cytoreductive Surgery and HIPEC Alone for Resectable Colorectal Peritoneal Metastases: Patient-Reported Outcomes of a Randomized Phase II Trial

Author

Bakkers, C., Rovers, K. P., Rijken, A., Simkens, G. A. A. M., Bonhof, C. S., Nienhuijs, S. W., Burger, J. W. A., Creemers, G. J. M., Brandt-Kerkhof, A. R. M., Tuynman, J. B., Aalbers, A. G. J., Wiezer, M. J., de Reuver, P. R., van Grevenstein, W. M. U., Hemmer, P. H. J., Punt, C. J. A., Tanis, P. J., Mols, F., and de Hingh, I. H. J. T.

Published
2023
Full Text
View/download PDF

4. Tumoren van dunne en dikke darm

Author

Tanis, P. J., Beets-Tan, R. G. H., Marijnen, C. A. M., Nagtegaal, I. D., Punt, C. J. A., van de Velde, C.J.H., editor, van der Graaf, W.T.A., editor, van Krieken, J.H.J.M., editor, and Marijnen, C.A.M., editor

Published
2017
Full Text
View/download PDF

8. Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer

Author

Researchgr. Nucleaire Geneeskunde, Cancer, Epi Kanker Team B, Team Medisch, Circulatory Health, Punt, C J A, Heinemann, V, Maughan, T, Cremolini, C, Van Cutsem, E, McDermott, R, Bodoky, G, André, T, Osterlund, P, Teske, A J, Pfeiffer, P, Researchgr. Nucleaire Geneeskunde, Cancer, Epi Kanker Team B, Team Medisch, Circulatory Health, Punt, C J A, Heinemann, V, Maughan, T, Cremolini, C, Van Cutsem, E, McDermott, R, Bodoky, G, André, T, Osterlund, P, Teske, A J, and Pfeiffer, P

Published
2023

9. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial

Author

Buisman, F. E., Homs, M. Y. V., Grünhagen, D. J., Filipe, W. F., Bennink, R. J., Besselink, M. G. H., Borel Rinkes, I. H. M., Bruijnen, R. C. G., Cercek, A., D’Angelica, M. I., van Delden, O. M., Donswijk, M. L., van Doorn, L., Doornebosch, P. G., Emmering, J., Erdmann, J. I., IJzerman, N. S., Grootscholten, C., Hagendoorn, J., Kemeny, N. E., Kingham, T. P., Klompenhouwer, E. G., Kok, N. F. M., Koolen, S., Kuhlmann, K. F. D., Kuiper, M. C., Lam, M. G. E., Mathijssen, R. H. J., Moelker, A., Oomen-de Hoop, E., Punt, C. J. A., te Riele, W. W., Roodhart, J. M. L., Swijnenburg, R. J., Prevoo, W., Tanis, P. J., Vermaas, M., Versleijen, M. W. J., Veuger, F. P., Weterman, M. J., Verhoef, C., and Groot Koerkamp, B.

Published
2019
Full Text
View/download PDF

12. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours : a multicentre retrospective observational cohort study

Author

Osterlund, P., Kinos, S., Pfeiffer, P., Salminen, T., Kwakman, J. J. M., Frodin, J-E, Shah, C. H., Sorbye, H., Ristamaki, R., Halonen, P., Soveri, L. M., Heerva, E., Algars, A., Barlund, M., Hagman, H., McDermott, R., O'Reilly, M., Röckert, R., Liposits, G., Kallio, R., Flygare, P., Teske, A. J., van Werkhoven, E., Punt, C. J. A., Glimelius, Bengt, Osterlund, P., Kinos, S., Pfeiffer, P., Salminen, T., Kwakman, J. J. M., Frodin, J-E, Shah, C. H., Sorbye, H., Ristamaki, R., Halonen, P., Soveri, L. M., Heerva, E., Algars, A., Barlund, M., Hagman, H., McDermott, R., O'Reilly, M., Röckert, R., Liposits, G., Kallio, R., Flygare, P., Teske, A. J., van Werkhoven, E., Punt, C. J. A., and Glimelius, Bengt

Abstract

Background: Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity, but evidence regarding the safety of switching to S-1 after 5-FU- or capecitabine-associated cardiotoxicity is scarce. Patients and methods: This retrospective study (NCT04260269) was conducted at 13 centres in 6 countries. The primary endpoint was recurrence of cardiotoxicity after switch to S-1-based treatment due to 5-FU- or capecitabine-related cardiotoxicity: clinically meaningful if the upper boundary of the 95% confidence interval (CI; by competing risk) is not including 15%. Secondary endpoints included cardiac risk factors, diagnostic work-up, treatments, outcomes, and timelines of cardiotoxicity. Results: Per protocol, 200 patients, treated between 2011 and 2020 [median age 66 years (range 19-86); 118 (59%) males], were included. Treatment intent was curative in 145 (73%). Initial cardiotoxicity was due to capecitabine (n = 170), continuous infusion 5-FU (n = 22), or bolus 5-FU (n = 8), which was administered in combination with other chemotherapy, targeted agents, or radiotherapy in 133 patients. Previous cardiovascular comorbidities were present in 99 (50%) patients. Cardiotoxic events (n = 228/200) included chest pain (n = 125), coronary syndrome/ infarction (n = 69), arrhythmia (n = 22), heart failure/cardiomyopathy (n = 7), cardiac arrest (n = 4), and malignant hypertension (n = 1). Cardiotoxicity was severe or life-threatening in 112 (56%) patients and led to permanent capecitabine/5-FU discontinuation in 192 (96%). After switch to S-1, recurrent cardiotoxicity was observed in eight (4%) patients (95% CI 2.02-7.89, primary endpoint met). Events were limited to grade 1-2 and occurred at a median of 16 days (interquartile range 7-67) from therapy switch. Baseline ischemic heart disease was a risk factor for recurrent cardiotoxicity (odds ratio 6.18

Published
2022
Full Text
View/download PDF

13. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours:a multicentre retrospective observational cohort study

Author

Osterlund, P. (P.), Kinos, S. (S.), Pfeiffer, P. (P.), Salminen, T. (T.), Kwakman, J. J. (J. J. M.), Frödin, J.-E. (J.-E.), Shah, C. H. (C. H.), Sorbye, H. (H.), Ristamäki, R. (R.), Halonen, P. (P.), Soveri, L. .. (L .M.), Heervä, E. (E.), Ålgars, A. (A.), Bärlund, M. (M.), Hagman, H. (H.), McDermott, R. (R.), O’Reilly, M. (M.), Röckert, R. (R.), Liposits, G. (G.), Kallio, R. (R.), Flygare, P. (P.), Teske, A. J. (A. J.), van Werkhoven, E. (E.), Punt, C. J. (C. J A.), B. Glimelius, B. G. (B. Glimelius), Osterlund, P. (P.), Kinos, S. (S.), Pfeiffer, P. (P.), Salminen, T. (T.), Kwakman, J. J. (J. J. M.), Frödin, J.-E. (J.-E.), Shah, C. H. (C. H.), Sorbye, H. (H.), Ristamäki, R. (R.), Halonen, P. (P.), Soveri, L. .. (L .M.), Heervä, E. (E.), Ålgars, A. (A.), Bärlund, M. (M.), Hagman, H. (H.), McDermott, R. (R.), O’Reilly, M. (M.), Röckert, R. (R.), Liposits, G. (G.), Kallio, R. (R.), Flygare, P. (P.), Teske, A. J. (A. J.), van Werkhoven, E. (E.), Punt, C. J. (C. J A.), and B. Glimelius, B. G. (B. Glimelius)

Abstract

Background: Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity, but evidence regarding the safety of switching to S-1 after 5-FU- or capecitabine-associated cardiotoxicity is scarce. Patients and methods: This retrospective study (NCT04260269) was conducted at 13 centres in 6 countries. The primary endpoint was recurrence of cardiotoxicity after switch to S-1-based treatment due to 5-FU- or capecitabine-related cardiotoxicity: clinically meaningful if the upper boundary of the 95% confidence interval (CI; by competing risk) is not including 15%. Secondary endpoints included cardiac risk factors, diagnostic work-up, treatments, outcomes, and timelines of cardiotoxicity. Results: Per protocol, 200 patients, treated between 2011 and 2020 [median age 66 years (range 19-86); 118 (59%) males], were included. Treatment intent was curative in 145 (73%). Initial cardiotoxicity was due to capecitabine (n = 170), continuous infusion 5-FU (n = 22), or bolus 5-FU (n = 8), which was administered in combination with other chemotherapy, targeted agents, or radiotherapy in 133 patients. Previous cardiovascular comorbidities were present in 99 (50%) patients. Cardiotoxic events (n = 228/200) included chest pain (n = 125), coronary syndrome/infarction (n = 69), arrhythmia (n = 22), heart failure/cardiomyopathy (n = 7), cardiac arrest (n = 4), and malignant hypertension (n = 1). Cardiotoxicity was severe or life-threatening in 112 (56%) patients and led to permanent capecitabine/5-FU discontinuation in 192 (96%). After switch to S-1, recurrent cardiotoxicity was observed in eight (4%) patients (95% CI 2.02-7.89, primary endpoint met). Events were limited to grade 1-2 and occurred at a median of 16 days (interquartile range 7-67) from therapy switch. Baseline ischemic heart disease was a risk factor for recurrent cardiotoxicity (odds rat

Published
2022

14. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study

Author

MS Medische Oncologie, Team Medisch, Circulatory Health, Epi Kanker Team B, Researchgr. Nucleaire Geneeskunde, Cancer, Osterlund, P, Kinos, S, Pfeiffer, P, Salminen, T, Kwakman, J J M, Frödin, J-E, Shah, C H, Sorbye, H, Ristamäki, R, Halonen, P, Soveri, L M, Heervä, E, Ålgars, A, Bärlund, M, Hagman, H, McDermott, R, O'Reilly, M, Röckert, R, Liposits, G, Kallio, R, Flygare, P, Teske, A J, van Werkhoven, E, Punt, C J A, Glimelius, B, MS Medische Oncologie, Team Medisch, Circulatory Health, Epi Kanker Team B, Researchgr. Nucleaire Geneeskunde, Cancer, Osterlund, P, Kinos, S, Pfeiffer, P, Salminen, T, Kwakman, J J M, Frödin, J-E, Shah, C H, Sorbye, H, Ristamäki, R, Halonen, P, Soveri, L M, Heervä, E, Ålgars, A, Bärlund, M, Hagman, H, McDermott, R, O'Reilly, M, Röckert, R, Liposits, G, Kallio, R, Flygare, P, Teske, A J, van Werkhoven, E, Punt, C J A, and Glimelius, B

Published
2022

15. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study

Author

Goey, K. K. H., Elias, S. G., van Tinteren, H., Laclé, M. M., Willems, S. M., Offerhaus, G. J. A., de Leng, W. W. J., Strengman, E., ten Tije, A. J., Creemers, G.-J. M., van der Velden, A., de Jongh, F. E., Erdkamp, F. L. G., Tanis, B. C., Punt, C. J. A., and Koopman, M.

Published
2017
Full Text
View/download PDF

28. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial†

Author

Breugom, A. J., van Gijn, W., Muller, E. W., Berglund, Å., van den Broek, C. B. M., Fokstuen, T., Gelderblom, H., Kapiteijn, E., Leer, J. W. H., Marijnen, C. A. M., Martijn, H., Meershoek-Klein Kranenbarg, E., Nagtegaal, I. D., Påhlman, L., Punt, C. J. A., Putter, H., Roodvoets, A. G. H., Rutten, H. J. T., Steup, W. H., Glimelius, B., and van de Velde, C. J. H.

Published
2015
Full Text
View/download PDF

30. Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data

Author

Onderzoek Medische Oncologie, Cancer, Genetica Medische Informatica, Child Health, Biostatistiek Onderwijs, JC onderzoeksprogramma Methodologie, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Hamers, P A H, Elferink, M A G, Stellato, R K, Punt, C J A, May, A M, Koopman, M, Vink, G R, Onderzoek Medische Oncologie, Cancer, Genetica Medische Informatica, Child Health, Biostatistiek Onderwijs, JC onderzoeksprogramma Methodologie, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Hamers, P A H, Elferink, M A G, Stellato, R K, Punt, C J A, May, A M, Koopman, M, and Vink, G R

Published
2021

37. Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study

Author

Andre, T., Amonkar, M., Norquist, J., Shiu, K-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J., Smith, D., Garcia-Carbonero, R., Sevilla, I., de la Fouchardiere, C., Rivera, F., Elez, E., Diaz, L. A., Yoshino, T., Van Cutsem, E., Yang, P., Farooqui, M. Z. H., and Le, D.

Published
2020

39. Multicentre study of short-course radiotherapy, systemic therapy and resection/ablation for stage IV rectal cancer

Author

Kok, E. N. D., Kok, E. N. D., Havenga, K., Tanis, P. J., de Wilt, J. H. W., Hagendoorn, J., Peters, F. P., Buijsen, J., Rutten, H. J. T., Kuhlmann, K. E. D., Beets, G. L., Aalbers, A. G. J., Kok, N. F. M., Ruers, T. J. M., Kobus, C. B. H. A., Siemons, S., Grootscholten, C., Dewit, L. G. H., van den Berg, J. G., Zavrakidis, null, de Jong, K. P., Hospers, G. A. P., Karrenbeld, A., Geijsen, E. D., Punt, C. J. A., Rutten, H., Radema, S., Intven, M. P. W., Roodhart, J. M. L., Holman, F., Kapiteijn, E., Melenhorst, J., Cnossen, J. S., Creemers, G-J M., Dutch Stage IV Rectal Canc Grp, Kok, E. N. D., Kok, E. N. D., Havenga, K., Tanis, P. J., de Wilt, J. H. W., Hagendoorn, J., Peters, F. P., Buijsen, J., Rutten, H. J. T., Kuhlmann, K. E. D., Beets, G. L., Aalbers, A. G. J., Kok, N. F. M., Ruers, T. J. M., Kobus, C. B. H. A., Siemons, S., Grootscholten, C., Dewit, L. G. H., van den Berg, J. G., Zavrakidis, null, de Jong, K. P., Hospers, G. A. P., Karrenbeld, A., Geijsen, E. D., Punt, C. J. A., Rutten, H., Radema, S., Intven, M. P. W., Roodhart, J. M. L., Holman, F., Kapiteijn, E., Melenhorst, J., Cnossen, J. S., Creemers, G-J M., and Dutch Stage IV Rectal Canc Grp

Abstract

Background The optimal treatment sequence for patients with rectal cancer and synchronous liver metastases remains unclear. The aim of this study was to evaluate the feasibility and effectiveness of short-course pelvic radiotherapy (5 x 5 Gy) followed by systemic therapy and local treatment of all tumour sites in patients with potentially curable stage IV rectal cancer in daily practice.Methods This was a retrospective study performed in eight tertiary referral centres in the Netherlands. Patients aged 18 years or above with rectal cancer and potentially resectable liver +/- extrahepatic metastases, treated between 2010 and 2015, were eligible. Main outcomes included full completion of treatment schedule, symptom control and survival.Results In total, 169 patients were included with a median follow-up of 49 center dot 5 (95 pr cent c.i. 43 center dot 6 to 55 center dot 6) months. The completion rate for the entire treatment schedule was 65 center dot 7 per cent. Three-year progression-free survival and overall survival (OS) rates were 24 center dot 2 (95 per cent c.i. 16 center dot 6 to 31 center dot 6) and 48 center dot 8 (40 center dot 4 to 57 center dot 2) per cent respectively. Median OS of patients who responded well and completed the treatment schedule was 51 center dot 5 months, compared with 15 center dot 1 months for patients who did not complete the treatment (P <0 center dot 001). Adequate symptom control of the primary tumour was achieved in 87 center dot 0 per cent of all patients.Conclusion Multimodal treatment is palliative in most patients, and associated with good survival rates in those able to complete the schedule.

Published
2020

40. Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials

Author

MS Medische Oncologie, Cancer, MS CGO, Externen Med. Onco, Belkouz, A, Wilmink, J W, Haj Mohammad, N, Hagendoorn, J, de Vos-Geelen, J, Dejong, C H C, Homs, M Y V, Groot Koerkamp, B, van Gulik, T M, van Oijen, M G H, Punt, C J A, Klümpen, H, MS Medische Oncologie, Cancer, MS CGO, Externen Med. Onco, Belkouz, A, Wilmink, J W, Haj Mohammad, N, Hagendoorn, J, de Vos-Geelen, J, Dejong, C H C, Homs, M Y V, Groot Koerkamp, B, van Gulik, T M, van Oijen, M G H, Punt, C J A, and Klümpen, H

Published
2020

46. Multicentre study of short-course radiotherapy, systemic therapy and resection/ablation for stage IV rectal cancer

Author

Kok, E N D, primary, Havenga, K, additional, Tanis, P J, additional, Wilt, J H W, additional, Hagendoorn, J, additional, Peters, F P, additional, Buijsen, J, additional, Rutten, H J T, additional, Kuhlmann, K F D, additional, Beets, G L, additional, Aalbers, A G J, additional, Kok, N F M, additional, Ruers, T J M, additional, Kobus, C B H A, additional, Siemons, S V, additional, Grootscholten, C, additional, Dewit, L G H, additional, Berg, J G, additional, Zavrakidis, I, additional, Jong, K P, additional, Hospers, G A P, additional, Karrenbeld, A, additional, Geijsen, E D, additional, Punt, C J A, additional, Rutten, H, additional, Radema, S, additional, Intven, M P W, additional, Roodhart, J M L, additional, Holman, F, additional, Kapiteijn, E, additional, Melenhorst, J, additional, Cnossen, J S, additional, and Creemers, G-J M, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results